Joëlla W Adams1, Brandon D L Marshall1, Nur Afiqah Mohd Salleh2, Rolando Barrios3, Seonaid Nolan4, M-J Milloy5. 1. Brown University School of Public Health, Department of Epidemiology, 121 South Main Street, Providence, RI 02903, United States. 2. British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada; Interdisciplinary Studies Graduate Program, University of British Columbia, 170-6371 Crescent Road, Vancouver, BC V6T 1Z2, Canada. 3. British Columbia Centre for Excellence in HIV/AIDS, 608-1081 Burrad Street, Vancouver, BC V6Z 1Y6, Canada. 4. British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada. 5. British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC V6Z 2A9, Canada; Department of Medicine, University of British Columbia, 2775 Laurel Street, 10th Floor, Vancouver, BC V5Z 1M9, Canada. Electronic address: bccsu-mjsm@bccsu.ubc.ca.
Abstract
BACKGROUND: Women living with HIV who use illicit drugs may be particularly vulnerable to HIV-1 RNA viral load (VL) rebound. METHODS: We used longitudinal data from 2006 to 2017 to evaluate the impact of sociodemographic, behavioral, social-structural, and clinical factors on the hazard of viral rebound for women enrolled in the ACCESS study, a prospective cohort with systematic VL monitoring. Women were included if they achieved VL suppression (<50 copies/mL) following antiretroviral therapy (ART) initiation and had more than one study interview. Sociodemographic as well as substance use, social-structural, addiction treatment, and HIV clinical factors were evaluated as predictors of viral rebound (VL > 1000 copies/mL). Cox regressions using a recurrent events framework, time-varying covariates, robust standard errors, and a frailty component were used. RESULTS: Of the 185 women included, 62 (34%) experienced at least one viral rebound event over an 11-year period, accumulating a total of 87 viral rebound events. In adjusted analysis, stimulant use more than doubled the hazard of viral rebound (adjusted hazard ratio [AHR]: 2.35, 95% confidence interval [CI]: 1.07-5.14) while the only factor protective against viral rebound was receipt of opioid agonist treatment (OAT) in the past six months (AHR: 0.46, 95% CI: 0.26-0.81). After adjusting for ART adherence in the past six months, the effect of OAT was attenuated (AHR: 0.57, 95% CI: 0.32-1.02). CONCLUSIONS: Efforts to improve access to and retention within OAT programs and decrease stimulant use may improve rates of viral suppression for HIV-positive women who use illicit drugs.
BACKGROUND:Women living with HIV who use illicit drugs may be particularly vulnerable to HIV-1 RNA viral load (VL) rebound. METHODS: We used longitudinal data from 2006 to 2017 to evaluate the impact of sociodemographic, behavioral, social-structural, and clinical factors on the hazard of viral rebound for women enrolled in the ACCESS study, a prospective cohort with systematic VL monitoring. Women were included if they achieved VL suppression (<50 copies/mL) following antiretroviral therapy (ART) initiation and had more than one study interview. Sociodemographic as well as substance use, social-structural, addiction treatment, and HIV clinical factors were evaluated as predictors of viral rebound (VL > 1000 copies/mL). Cox regressions using a recurrent events framework, time-varying covariates, robust standard errors, and a frailty component were used. RESULTS: Of the 185 women included, 62 (34%) experienced at least one viral rebound event over an 11-year period, accumulating a total of 87 viral rebound events. In adjusted analysis, stimulant use more than doubled the hazard of viral rebound (adjusted hazard ratio [AHR]: 2.35, 95% confidence interval [CI]: 1.07-5.14) while the only factor protective against viral rebound was receipt of opioid agonist treatment (OAT) in the past six months (AHR: 0.46, 95% CI: 0.26-0.81). After adjusting for ART adherence in the past six months, the effect of OAT was attenuated (AHR: 0.57, 95% CI: 0.32-1.02). CONCLUSIONS: Efforts to improve access to and retention within OAT programs and decrease stimulant use may improve rates of viral suppression for HIV-positive women who use illicit drugs.
Authors: Conar R O'Neil; Alexis K Palmer; Suzy Coulter; Nadia O'Brien; Anya Shen; Wendy Zhang; Julio S G Montaner; Robert S Hogg Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2012-02-07
Authors: Sandra A Springer; Sarah Larney; Zahra Alam-Mehrjerdi; Frederick L Altice; David Metzger; Steven Shoptaw Journal: J Acquir Immune Defic Syndr Date: 2015-06-01 Impact factor: 3.731
Authors: Xiuhong Li; Joseph B Margolick; Craig S Conover; Sheila Badri; Sharon A Riddler; Mallory D Witt; Lisa P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2005-03-01 Impact factor: 3.731
Authors: Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Breanne E Biondi; Maureen Desabrais; Thomas Lincoln; Daniel J Skiest; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731
Authors: Joëlla W Adams; Kathleen A Brady; Yvonne L Michael; Baligh R Yehia; Florence M Momplaisir Journal: Clin Infect Dis Date: 2015-08-11 Impact factor: 9.079
Authors: Lindsey A Richardson; Thomas H Kerr; Sabina Dobrer; Cathy M Puskas; Silvia A Guillemi; Julio S G Montaner; Evan Wood; M-J S Milloy Journal: AIDS Date: 2015-11-28 Impact factor: 4.177
Authors: Jessica J Wyse; Kathleen A McGinnis; E Jennifer Edelman; Adam J Gordon; Ajay Manhapra; David A Fiellin; Brent A Moore; P Todd Korthuis; Amy J Kennedy; Benjamin J Oldfield; Julie R Gaither; Kirsha S Gordon; Melissa Skanderson; Declan T Barry; Kendall Bryant; Stephen Crystal; Amy C Justice; Kevin L Kraemer Journal: AIDS Behav Date: 2021-09-08
Authors: Stephen Opoku; Samuel Asamoah Sakyi; Nana Kwame Ayisi-Boateng; Anthony Kwame Enimil; Ebenezer Senu; Richard Owusu Ansah; Bismark Dankwah Aning; Diana Atsieno Ojuang; Doreen Nafula Wekesa; Fatima Osman Ahmed; Chidinma B Okeke; Ama Darkoaa Sarfo Journal: AIDS Res Ther Date: 2022-05-25 Impact factor: 2.846
Authors: Susmita Sil; Annadurai Thangaraj; Ernest T Chivero; Fang Niu; Muthukumar Kannan; Ke Liao; Peter S Silverstein; Palsamy Periyasamy; Shilpa Buch Journal: Neurosci Lett Date: 2021-03-29 Impact factor: 3.197
Authors: Amy J Kennedy; Kathleen A McGinnis; Jessica S Merlin; E Jennifer Edelman; Adam J Gordon; P Todd Korthuis; Melissa Skanderson; Emily C Williams; Jessica Wyse; Benjamin Oldfield; Kendall Bryant; Amy Justice; David A Fiellin; Kevin L Kraemer Journal: J Subst Abuse Treat Date: 2021-05-29